Treatment of hepatic fibrosis: Almost there

Current Gastroenterology Reports

Volumn 5, Issue 1, 2003, Pages 48-56

  Albanis, Efsevia ^b   Safadi, Rifaat ^b   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIOXIDANT; CAMOSTAT MESILATE; CORTICOSTEROID DERIVATIVE; CYTOKINE; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; GLIOTOXIN; MACROPHAGE CHEMOTACTIC FACTOR; METALLOPROTEINASE INHIBITOR; NITRIC OXIDE DONOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PROTEINASE INHIBITOR; S ADENOSYLMETHIONINE; SILYMARIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL ACTIVATION; CELL PROLIFERATION; COLLAGEN DEGRADATION; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROGENESIS; GENE THERAPY; HUMAN; IMMUNOMODULATION; LIVER CELL; LIVER FIBROSIS; LIVER PROTECTION; LIVER TRANSPLANTATION; NEUTROPHIL CHEMOTAXIS; PATHOGENESIS; RETROSPECTIVE STUDY; REVIEW; STELLATE CELL; CYTOLOGY; LIVER; LIVER CIRRHOSIS; PATHOPHYSIOLOGY;

HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 0038621884     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0009-7     Document Type: Review

References (50)

1. Friedman SL: Molecular regulation of hepatic fibrosis: an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.
2. Friedman SL, Maher JJ, Bissell DM: Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000, 32:1403-1408.
3. Pinzani M, Marra F: Cytokine receptors and signaling during stellate cell activation. Semin Liver Dis 2001, 21:397-416.
4. Bachem MG, Schneider E, Gross H, et al.: Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998, 115:421-432.
5. Iredale JP: Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001, 21:427-436.
6. Wong L, Yamasaki G, Johnson RJ, Friedman SL: Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994, 94:1563-1569.
7. Rockey DC: Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337-350.
8. Shao R, Rockey DC: Effects of endothelins on hepatic stellate cell synthesis of endothelin-1 during hepatic wound healing. J Cell Physiol 2002, 191:342-350.
9. Paradis V, Dargere D, Bonvoust F, et al.: Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002, 82:767-774.
10. Saxena NK, Ikeda K, Rockey DC, et al.: Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002, 35:762-771.
11. Ikejima K, Honda H, Yoshikawa M, et al.: Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001, 34:288-297.
12. Benyon D, Arthur MJP: Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001, 21:373-384.
13. Iredale JP: Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997, 29:43-54.
14. Marra F, Romanelli RG, Pastacaldi S, et al.: Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999, 29:140-148.
15. Ikeda K, Wakahara T, Wang YQ et al.: In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999, 29:1760-1767.
16. Bataller R, Brenner DA: Stellate cells as a target for treatment of liver fibrosis. Semin Liver Dis 2001, 21:437-452.
17. Bonis PA, Friedman SL, Kaplan MM: Is liver fibrosis reversible? N Engl J Med 2001, 344:452-454.
18. Kweon YO, Goodman ZD, Dienstag JL, et al.: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-755.
19. Poynard T, McHutchison J, Manns M, et al.: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-1313.
20. Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517-524.
21. Cotler SJ, Jakate S, Jensen DM: Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy. J Clin Gastroenterol 2001, 32:428-430.
22. Pietrangelo A: Metals, oxidative stress, and hepatic fibrogenesis. Semin Liver Dis 1996, 16:13-30.
23. Houglum K, Venkataramani A, Lyche K, Chojkier M: A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997, 113:1069-1073.
24. Houglum K, Ramm GA, Crawford DH, et al.: Excess iron induces hepatic oxidative stress and transforming growth factor beta1 in genetic hemochromatosis. Hepatology 1997, 26:605-610.
25. Pietrangelo A, Borella F, Casalgrandi G, et al.: Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995, 109:1941-1949.
26. Ferenci P, Dragosics B, Dittrich H, et al.: Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatology 1989, 9:105-110.
27. Rockey DC, Chung JJ: Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994, 42:660-670.
28. King TE, Jr: Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 2000, 342:974-975.
29. Marra F, Efsen E, Romanelli RG, et al.: Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000, 119:466-478.
30. Kon K, Ikejima K, Hirose M, et al.: Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002, 291:55-61.
31. Galli A, Crabb DW, Ceni E, et al.: Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002, 122:1924-1940.
32. Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519-525.
33. Frank S, Stallmeyer B, Kampfer H, et al.: Leptin enhances wound re-epithelialization and constitutes a direct function of leptin in skin repair. J Clin Invest 2000, 106:501-509.
34. Leclercq IA, Farrell GC, Schriemer R, Robertson GR: Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002, 37:206-213.
35. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
36. Waltenberger J: Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation 1997, 96:4083-4094.
37. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
38. Kawada N, Seki S, Kuroki T, Kaneda K: ROCK inhibitor Y-27632 attenuates stellate cell contraction and portal pressure increase induced by endothelin-1. Biochem Biophys Res Commun 1999, 266:296-300.
39. Tada S, Iwamoto H, Nakamuta M, et al.: A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine- induced hepatic fibrosis in rats. J Hepatol 2001, 34:529-536.
40. George J, Roulot D, Koteliansky VE, Bissell DM: In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999, 96:12719-12724.
41. Okuno M, Akita K, Moriwaki H, et al.: Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001, 120:1784-1800.
42. Ueki T, Kaneda Y, Tsutsui H, et al.: Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999, 5:226-230.
43. Wang YJ, Wang SS, Bickel M, Bissell DM: Two novel antifibrotics, HOE 077 and Safironil, modulate stellate cell activation in rat liver injury: differential effects in males and females. Am J Pathol 1998, 152:279-287.
44. Stefanovic B, Schnabl B, Brenner DA: inhibition of collagen alpha1(I) expression by the 5′ stem-loop as a molecular decoy. J Biol Chem 2002, 277:18229-18237.
45. Rockey DC, Chung JJ: Endothelin antagonism in experimental hepatic fibrosis: implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996, 98:1381-1388.
46. Yu Q, Shao R, Qian HS, et al.: Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000, 105:741-748.
47. Iredale JP, Benyon RC, Pickering J, et al.: Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998, 102:538-549.
48. Wright MC, Issa R, Smart DE, et al.: Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001, 121:685-698.
49. Salgado S, Garcia J, Vera J, et al.: Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000, 2:545-551.
50. Beljaars L, Meijer DK, Poelstra K: Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front Biosci 2002, 7:e214-e222.